Copyright
©The Author(s) 2021.
World J Cardiol. Aug 26, 2021; 13(8): 271-297
Published online Aug 26, 2021. doi: 10.4330/wjc.v13.i8.271
Published online Aug 26, 2021. doi: 10.4330/wjc.v13.i8.271
Pathology | What to assess? (echo view) | Cut-off mm (mean mm) | If pathological, what to assess? (echo view) | Cut-off mm (mean mm) |
HCM | LV Max end-diastolic wall thickness | M white 15 (10); M Afro-American 16 (11.5); F white 11; F Afro-American 13 (9.5); M/F adolescent 16 (12) | LV wall thickness distribution | Asymmetric (HCM) |
LV end diastolic diameter (A4C) | M 70 (55); F 66 (49); Adolescent 60 (51) | |||
LV mass/BSA | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |||
LVOT obstruction | ||||
E/A (A4C) | 1.3 (1.93) | |||
DCM | LV end diastolic diameter (PLAX) | M 70 (50); F 66 (49); Adolescent 60 (51) | EF (A4C) | 55% (64%) |
LVNC | LV trabeculation | NC/C layer ratio > 2.0 in systole | EF (A4C) | 55% (64%) |
Thickness of compact layer in systole | 8 | |||
E/A (A4C) | 1.3 (1.93) | |||
ARVC | RVOT/BSA (PSAX) | > 21 mm/m2 | RV inflow (A4C)/ LV end diastolic diameter (PLAX) | > 0.9 |
RVOVT/BSA (PLAX) | > 19 mm/m2 | RV wall motion abnormalities | ||
RV FAC | 33% | |||
Aortic dilatation | Aortic valve max dimension (PLAX) | M 40 (32); F 34 (28) | Other congenital defects (BAV) | |
Ascending aorta dimension (PLAX) | Aortic regurgitation | |||
Mitral prolapse | Mitral prolapse (PLAX) | Abnormal systolic bulging of leaflets > 2 mm toward LA | Mitral regurgitation | |
PAPS (A4C) | 40 mmHg (24 mmHg) | |||
Pulmonary veins flow | Reverse | |||
EF (A4C) | 55% (64%) | |||
LV mass/BSA | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |||
LAVI | M 36 mm/m2 (28 mm/m2); F 33 mm/m2 (26.5 mm/m2) | |||
AOCA | Coronary arteries origin (PSAX) | |||
BAV | Aortic morphology (PSAX) | Aortic stenosis | ||
Aortic regurgitation | ||||
Aortic root max dimension (PLAX) | M 40 (32); F 34 (28) | |||
Other congenital defects (coarctation of the aorta, interrupted aortic arch, patent ductus arteriosus, coronary anomaly or hypoplastic left heart, as well as Williams or Turner syndrome) | ||||
ASD | ASD | RV dimension (A4C) | Basal RV: M 55 (43.5), F 49 (39); Medial RV: M 47 (34), F 43 (32); Longitudinal RV: M 109 (89), F 100 (82) | |
RA area/BSA (A4C) | M 28 mm/m2 (19.5 mm/m2); F 24 mm/m2 (15.5 mm/m2) | |||
PAPS (A4C) | 40 mmHg (24 mmHg) | |||
VSD | VSD | LV mass/BSA (PLAX) | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |
PAPS (A4C) | 40 mmHg (24 mmHg) | |||
Aortic regurgitation | ||||
Other congenital defects (aneurysm of Valsalva sinus, ToF, TGA, DCRV) | ||||
PDA | PDA (PSAX) | LA/Aortic root ratio | ≥ 1.4 | |
LV mass/BSA (PLAX) | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |||
PAPS (A4C) | 40 mmHg (24 mmHg) | |||
Pulmonary artery size (PSAX) | ||||
RV dimension (A4C) | Basal RV: M 55 (43.5), F 49 (39); Medial RV: M 47 (34), F 43 (32); Longitudinal RV: M 109 (89), F 100 (82) | |||
RA area/BSA (A4C) | M 28 mm/m2 (19.5 mm/m2); F 24 mm/m2 (15.5 mm/m2) | |||
Other congenital defects (COA, pulmonary atresia) | ||||
COA | COA (PSAX) | Aortic stenosis | ||
Mitral stenosis | ||||
LV mass/BSA (PSAX) | M 117 mm/m2 (83 mm/m2); F 143 mm/m2 (101 mm/m2) | |||
EF (A4C) | 55% (64%) | |||
Other congenital defects (BAV, ascending aortic aneurysm) | ||||
Myocarditis | EF (A4C) | 55% (64%) | ||
LV wall motion abnormalities | ||||
Pericardial effusion | ||||
Increased LV wall thickness | ||||
Pericarditis | Pericardial effusion | |||
Kawasaki disease | Coronary artery abnormalities | |||
EF (A4C) | 55% (64%) | |||
LV wall motion abnormalities | ||||
Mitral regurgitation | ||||
Aortic regurgitation | ||||
Pericardial effusion |
- Citation: Palermi S, Serio A, Vecchiato M, Sirico F, Gambardella F, Ricci F, Iodice F, Radmilovic J, Russo V, D'Andrea A. Potential role of an athlete-focused echocardiogram in sports eligibility. World J Cardiol 2021; 13(8): 271-297
- URL: https://www.wjgnet.com/1949-8462/full/v13/i8/271.htm
- DOI: https://dx.doi.org/10.4330/wjc.v13.i8.271